Anlon Healthcare IPO Review: Date, Price Band, GMP & Allotment
25 August 2025 · Sachin Gadekar
A detailed review of Anlon Healthcare IPO covering dates, price band, company financials, strengths, and whether you should apply.
Introduction
The Indian pharmaceutical sector continues to attract investors with strong IPO launches, and Anlon Healthcare Limited is the latest company gearing up to list on the stock market. Backed by a decade of experience in manufacturing pharma intermediates and active pharmaceutical ingredients (APIs), the company is opening its IPO in August 2025.
This Anlon Healthcare IPO review will cover key details such as IPO date, price band, lot size, financial performance, strengths, risks, and subscription guidance. For investors exploring upcoming IPOs or unlisted shares, platforms like ultra make it simple to participate and diversify portfolios.
Anlon Healthcare IPO Details
| Particulars | Details |
|---|---|
| IPO Type | Book Built Issue |
| IPO Size | ₹121.03 Crores |
| Fresh Issue | 1.33 Crore Shares |
| Face Value | ₹10 per share |
| Price Band | ₹86 – ₹91 per share |
| Lot Size | 164 shares |
| Minimum Investment | ₹14,104 (1 lot) |
| Listing At | NSE, BSE |
| IPO Open Date | August 26, 2025 |
| IPO Close Date | August 29, 2025 |
| Allotment Finalization | September 1, 2025 |
| Refund Initiation | September 2, 2025 |
| Credit of Shares | September 2, 2025 |
| Listing Date | September 3, 2025 |
| Book Running Lead Manager | Interactive Financial Services Ltd. |
| Registrar | KFin Technologies Ltd. |
Anlon Healthcare IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB | Not less than 75% of Net Issue |
| NII | Not less than 15% of Net Issue |
| Retail | Not more than 10% of Net Issue |
IPO Lot Size & Investment Details
| Application Type | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,104 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
About Anlon Healthcare Limited
Incorporated in 2013, Anlon Healthcare Limited is engaged in the manufacturing of pharmaceutical intermediates and active pharmaceutical ingredients (APIs).
Pharma Intermediates: These are critical raw materials or advanced intermediates used for manufacturing APIs.
APIs: Active Pharmaceutical Ingredients are the core therapeutic components used in medicines, nutraceuticals, personal care products, and veterinary health products.
Key Highlights:
Manufactures high-purity products conforming to IP, BP, EP, JP, and USP pharmacopeia standards.
Offers custom manufacturing solutions for complex chemicals.
Holds Drug Master File (DMF) approvals from ANVISA, NMPA, and PMDA.
Filed 21 DMFs globally and working on Ketoprofen & Dexketoprofen Trometamol approvals.
Team of 34 professionals, including 24 science graduates, working across four labs.
Product portfolio: 65 commercialized products, 28 pilot stage, and 49 at lab scale.
Competitive Strengths
Diverse Product Portfolio – Over 65 commercialized pharma intermediates and APIs.
Strong Regulatory Approvals – Multiple DMF filings with international agencies.
Scalable Business Model – High entry barriers due to customer approval cycles.
Quality Assurance – In-house labs ensuring compliance with global standards.
Experienced Management – Strong promoters with technical expertise.
Financial Performance of Anlon Healthcare
| Period Ended | Assets (₹ Cr) | Total Income (₹ Cr) | PAT (₹ Cr) | EBITDA (₹ Cr) | Net Worth (₹ Cr) | Borrowings (₹ Cr) |
|---|---|---|---|---|---|---|
| Mar 2023 | 111.55 | 113.12 | 5.82 | 12.66 | 7.37 | 66.39 |
| Mar 2024 | 128.00 | 66.69 | 9.66 | 15.57 | 21.03 | 74.56 |
| Mar 2025 | 181.30 | 120.46 | 20.52 | 32.38 | 80.42 | 58.35 |
Should You Invest in Anlon Healthcare IPO?
The Anlon Healthcare IPO provides exposure to India’s growing pharmaceutical sector. With a strong product portfolio, regulatory approvals, and robust financial performance, the company looks well-positioned for long-term growth.
However, investors must weigh the risks of industry competition and SME IPO volatility. For long-term investors seeking exposure to pharma growth, the IPO looks promising.
Risks to Consider
High Industry Competition – Pharma API space is competitive.
Regulatory Challenges – Business depends on strict global approvals.
Working Capital Needs – Pharma manufacturing requires significant liquidity.
SME IPO Risks – Higher volatility and lower liquidity post-listing.
FAQs on Anlon Healthcare IPO
Q1. What is the Anlon Healthcare IPO date?
The IPO opens on August 26, 2025 and closes on August 29, 2025.
Q2. What is the Anlon Healthcare IPO price band?
The price band is fixed at ₹86 – ₹91 per share.
Q3. What is the minimum investment for retail investors?
Retail investors can apply for 1 lot = 164 shares = ₹14,104.
Q4. When is the Anlon Healthcare IPO allotment date?
The allotment is expected to be finalized on September 1, 2025.
Q5. When will Anlon Healthcare IPO list?
The tentative listing date is September 3, 2025, on NSE and BSE.
Q6. Is Anlon Healthcare IPO a good buy?
The IPO looks promising due to strong financial growth and industry outlook, but investors should evaluate risks before investing.
Conclusion
The Anlon Healthcare IPO review highlights a strong financial track record, scalable product portfolio, and promising growth prospects in the pharma sector. While regulatory and industry risks exist, the IPO may appeal to investors with a long-term horizon.
With Ultra, you not only get access to upcoming IPOs like Anlon Healthcare but also explore unlisted shares, pre-IPO opportunities, and alternative investments — all in one digital platform.